Search results for "chronic"

showing 10 items of 3309 documents

Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension.

1998

The stimulation of autocrine and paracrine factors such as basic fibroblast- (bFGF) and platelet-derived (PDGF) growth factors mediates many of the growth-promoting actions of angiotensin II. The aim of this study was to evaluate the effect of chronic AT1-receptor blockade on plasma endothelin-1 (ET-1) and growth factors levels, and on left ventricular mass, in essential hypertension (EH). The study population consisted of 16 patients with mild-moderate EH, and 25 normotensive controls. In the EH patients under basal conditions, and after 3 and 6 months of chronic therapy with Losartan 50 mg/day, we measured serum levels of ET-1, bFGF and PDGF, and tumor necrosis factor (TNF). At the same t…

medicine.hormoneAdultMalemedicine.medical_specialtyAngiotensin receptorAmbulatory blood pressureHeart VentriclesEssential hypertensionLosartanEndothelinsAngiotensin Receptor AntagonistsInternal medicineBlood plasmaInternal MedicineMedicineHumansGrowth SubstancesAntihypertensive Agentsbusiness.industryEndothelinsMyocardiummedicine.diseaseAngiotensin IILosartanBlood pressureEndocrinologyChronic DiseaseHypertensionFemalebusinessmedicine.drugAmerican journal of hypertension
researchProduct

A pouch in the cervix: a strange diagnosis

2016

Anechoic cervical lesions are uncommon findings which may entail diagnostic and, therefore, management difficulties. Chronic cervicitis, bulky nabothian cysts, adenomyomas, niches (cesarean scar defects), congenital malformations, and pseudo-neoplastic glandular cervical lesions often raise diagnostic dilemmas; they may also mimic malignant lesions [1–4]. Other anechoic images worth considering are those produced by cystic changes after cervical trauma, lacerations, or extremely rare false passages resulting from cervical dilatation [5]. Methods

medicine.medical_specialty030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryChronic CervicitisAbnormal uterine bleedingObstetrics and GynecologyInterventional radiologyHysteroscopyCystic Change030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureCervical cystObstetrics and gynaecologyHysteroscopymedicineSurgeryRadiologyPouchCervical dilatationbusinessCervixGynecological Surgery
researchProduct

Cardiorenal syndrome type 4: From chronic kidney disease to cardiovascular impairment

2016

Cardiorenal syndrome type 4 (CRS type 4), or chronic renocardiac syndrome, has been defined as "chronic abnormalities in renal function leading to cardiac disease" and recognizes the extreme burden of cardiovascular disease (CVD) risk in patients with chronic kidney disease (CKD). CKD is common and increasingly recognized as a risk factor for CVD. Even though the treatment for CVD has dramatically improved over the past decades, it still takes responsibility for up to 50% of deaths in CKD patients. For this reason, patients with CKD should be thoroughly evaluated for cardiovascular risk factors that require careful management, given the significant burden of CRS type 4 on the healthcare sys…

medicine.medical_specialty030232 urology & nephrologyRenal functionCardiorenal syndromeDisease030204 cardiovascular system & hematologyurologic and male genital diseasesLeft ventricular hypertrophyAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular risk; Chronic kidney disease; Hypertension; Left ventricular hypertrophy; Atherosclerosis; Cardio-Renal Syndrome; Disease Progression; Humans; Hypertension; Hypertrophy Left Ventricular; Renal Dialysis; Renal Insufficiency Chronic; Risk Factors; Internal Medicine03 medical and health sciences0302 clinical medicineRenal DialysisRisk FactorsInternal medicineChronic kidney diseaseCardiorenal syndrome type 4medicineInternal MedicineHumansIn patientRenal InsufficiencyRenal Insufficiency ChronicRisk factorChronicIntensive care medicineCardio-Renal Syndromebusiness.industryLeft ventricular hypertrophyHypertrophymedicine.diseaseAtherosclerosisCardiovascular riskAtherosclerosis; Cardiorenal syndrome type 4; Cardiovascular riskLeft VentricularRenocardiac SyndromeAtherosclerosiHypertensionCardiologyDisease ProgressionHypertrophy Left VentricularbusinessKidney disease
researchProduct

SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia

2020

Abstract Sodium–glucose co-transporter-2 (SGLT2) inhibitors decreased cardiovascular (CV) events and improved renal outcomes in CV safety studies in type 2 diabetes melitus (T2DM) patients at high CV risk. Canagliflozin also improved kidney outcomes in diabetic kidney disease in the Canagliflozin and Renal Events in Diabetes and Nephropathy Clinical Evaluationtrial. More recently, the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial showed that dapagliflozin improved CV outcomes in patients with HF with or without diabetes. Protection from HF in non-diabetics was confirmed for empagliflozin in the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Fa…

medicine.medical_specialty030232 urology & nephrologyUrologyRenal functionType 2 diabetes030204 cardiovascular system & hematologyoutcomesNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusClinical endpointMedicineDapagliflozinAcademicSubjects/MED00340Editorial CommentsCanagliflozinTransplantationclinical trialsbusiness.industrySGLT2 inhibitormedicine.diseasemortalitychemistryNephrologybusinesschronic kidney diseaseKidney diseasemedicine.drugClinical Kidney Journal
researchProduct

Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology

2020

Self-care is essential in the long-term management of chronic heart failure. Heart failure guidelines stress the importance of patient education on treatment adherence, lifestyle changes, symptom monitoring and adequate response to possible deterioration. Self-care is related to medical and person-centred outcomes in patients with heart failure such as better quality of life as well as lower mortality and readmission rates. Although guidelines give general direction for self-care advice, health care professionals working with patients with heart failure need more specific recommendations. The aim of the management recommendations in this paper is to provide practical advice for health profe…

medicine.medical_specialty2013 ACCF/AHA GUIDELINElifestyleTreatment adherenceCardiologyheart failure/dk/atira/pure/subjectarea/asjc/2700/2705Heart failureNursing030204 cardiovascular system & hematologyAMERICAN-COLLEGEEXERCISE CAPACITYpatient education03 medical and health sciencesAIR-TRAVEL0302 clinical medicineQuality of life (healthcare)MEDICATIONQUALITY-OF-LIFEHealth careself-caremedicineHumansIn patientIntensive care medicineVENTRICULAR DYSFUNCTIONbusiness.industrySymptom managementOmvårdnadSelf‐careDisease ManagementPatient educationmedicine.diseaseLifestyle3. Good healthSelf CareHeart failureChronic DiseaseSelf careQuality of LifeCARDIOVASCULAR-DISEASESSelf-care; Heart failure; Lifestyle; Patient educationPosition PaperSelf-carebusinessCardiology and Cardiovascular MedicineREDUCED EJECTION FRACTIONPatient educationTASK-FORCE
researchProduct

Comment on “Chronic spontaneous urticaria exacerbation in a patient with COVID‐19: rapid and excellent response to omalizumab”

2020

medicine.medical_specialty2019-20 coronavirus outbreakUrticariaCoronavirus disease 2019 (COVID-19)ExacerbationSARS-CoV-2business.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Symptom Flare UpTreatment outcomeMEDLINECOVID-19OmalizumabDermatologyOmalizumabInternal medicineAnti-Allergic AgentsCorrespondenceHumansMedicineChronic Urticariabusinessmedicine.drugInternational Journal of Dermatology
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

Perioperative management of patients with suspected or severe infection with SARS-CoV-2 coronavirus programmed for the implementation of electronic d…

2020

At the end of 2019, a series of patients affected by lung infection of initially unknown aetiology with clinical presentations very similar to viral pneumonia were registered in China. Sequencing analysis of samples from the lower respiratory tract identified a new type of virus from the family Coronaviridae called SARS-CoV-2 as the causative agent of the outbreak; the agent responsible for the disease that was renamed COVID-19.1 Since then, millions of cases have been identified around the world. The World Health Organization (WHO) initially declared the infection to be a Public Health Emergency of International Concern, and later classed it as a pandemic.2, 3 The vast majority of coronavi…

medicine.medical_specialtyARDSeducation.field_of_studyRespiratory tract infectionsbusiness.industryRespiratory diseasePopulationChronic painGeneral MedicineDiseasemedicine.diseaseSpecial ArticlePneumoniaComplex regional pain syndromemedicineIntensive care medicinebusinesseducationRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Chronic spontaneous urticaria or autoinflammatory disease? The therapeutic effect of omalizumab in a pediatric patient.

2018

Chronic spontaneous urticaria (CSU) is a clinical condition characterized by spontaneous or inducible recurrent wheals. This condition may significantly affect quality of life of patients and of their families. Etiology is not identified in 25-85% of cases that are indicated as 'idiopathic', because all diagnostic tests are negative. Autoimmune processes may be present in 30-50% of patients, although a definite etiological diagnosis is seldom possible. Some patients, in fact, have autoantibodies against the high-affinity IgE receptor FceR1 or IgE. These patients show an increased incidence of anti-thyroid autoantibodies and represent 30-50% of the patients designated as having CSU. Familial…

medicine.medical_specialtyAbdominal painAllergyDermatologyOmalizumabOmalizumabCold urticariaImmunoglobulin E03 medical and health sciences0302 clinical medicineFamilial Cold Autoinflammatory Syndromeautoinflammatory diseasemedicine030212 general & internal medicine030203 arthritis & rheumatologybiologybusiness.industrymedicine.diseaseDermatologyRashchronic idiopathic urticariabiology.proteinEtiologymedicine.symptombusinessmedicine.drugThe Journal of dermatological treatment
researchProduct

Walking Ability and All-Cause Mortality in Older Women

2010

In this study self-reported ability to walk 2 km and six-minute walking test (6MWT) performance were examined as predictors of all-cause mortality in 434 women, aged 63-76 years. The primary outcome measure was all-cause mortality (follow-up: 8 years). Predictors were self-reported difficulties in walking 2 km and 6-min walking distance tertiles of ≤495, 496-560 and ≥561 m, and no test result due to refusal by the physician to grant permission to perform the test or participant's inability or unwillingness to perform the test. During the follow-up, 39 participants died. Participants reporting minor (age- and body mass index-adjusted hazard ratio 2.53, 95% confidence interval 1.12-5.69) or m…

medicine.medical_specialtyActivities of daily livingmedia_common.quotation_subjectPhysical Therapy Sports Therapy and RehabilitationWalkingRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsActivities of Daily LivingConfidence IntervalsDiseases in TwinsmedicineHealth Status IndicatorsHumansOrthopedics and Sports Medicine030212 general & internal medicineMortalityFinlandAgedmedia_commonExercise Tolerancebusiness.industryHazard ratioConfoundingCardiorespiratory fitnessMiddle AgedConfidence intervalTest (assessment)Chronic DiseaseExercise TestPhysical therapyWomen's HealthFemaleAptitudeSelf ReportRisk assessmentbusinesshuman activities030217 neurology & neurosurgeryInternational Journal of Sports Medicine
researchProduct